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eligible if age 60–80 years, had stage II-IV DLCL, and
had ECOG performance status of 0–2. Mean patient 
survival in each treatment arm and chemotherapy costs
during treatment (q3 weeks ¥ 8 cycles) were estimated
from trial data. The longest duration of follow-up was 34
months. We estimated survival and cost-effectiveness up
to a time horizon of 10 years. Survival for each IPI strata
was estimated using the Kaplan-Meier method; survival
after the longest observed time in the trial was estimated
using published mortality rates (Shipp, NEJM, 93).
French DRG payments were applied to trial data on 
hospital use and treatments for adverse events. French
drug prices and drug administration costs were used to
estimate the costs of R-CHOP and CHOP regimens.
Costs and survival were discounted at 3.0%. R-CHOP
increased survival from 56% to 63% at the time of last
follow-up (34 months).
RESULTS: The mean duration of survival was 820 days
for R-CHOP and 721 days for CHOP, resulting in a mean
increase in survival of 0.27 years. Extrapolating to 10
years, R-CHOP is projected to increase discounted mean
survival by 0.54 years. Therapy-related cost during the
trial period was 15,000 euros higher with R-CHOP, with
a cost per life-year gained (LYG) of 55,300 euros. Over
10 years, total added cost per patient was 15,270 euros
and the estimated cost per LYG was 28,410 euros.
CONCLUSIONS: R-CHOP increases chance of cure
compared with CHOP and is cost-effective compared
with other treatments in widespread use.
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OBJECTIVE: Our aim is to describe a model that can be
used to calculate the costs and life-years gained from any
given screening program, and for any particular combi-
nation of risk factors for colorectal cancer (CRC). A trial
cannot evaluate more than a handful of these programs,
which suggests there may be a role for mathematical 
modeling techniques in identifying the designs worth 
evaluating in an interventional study.
METHODS: We used a Markov process model with time-
dependent transition probabilities to generate data on the
cost-effectiveness of various lifetime screening programs.
Our model represents the evolution of colorectal cancer
by ﬁve states; polyp-free colon, colon with benign
tumor(s), asymptomatic carcinomic colon, symptomatic
colonic cancer and death. We considered that progression
is related to prognosis via the Duke’s classiﬁcation system.
We have chosen a cycle length of one year for our model.
The outcome measure used is life expectancy from birth.
RESULTS: Our results suggest that with frequent 
screening the detrimental effects of genetic risk on life
expectancy can be almost completely countered. Screen-
ing can actually be cheaper than not screening, when costs
of treatment are included, especially for high-risk indi-
viduals. Hemoccult followed by colonoscopy if positive
is much cheaper than colonoscopy alone and, if carried
out frequently, almost as effective. Altering the age of ﬁrst
screening has a much less important effect on costs and
beneﬁts than altering the frequency. In order to counter
the effect of genetic risk on mortality, screening has to
begin much earlier for men than women.
CONCLUSIONS: Hemoccult followed by colonoscopy if
positive is a favorable strategy, even for high-risk groups,
but that the optimal frequency of screening is likely to
depend on gender and genetic susceptibility. These results
may be useful in designing future CRC screening trials.
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OBJECTIVE: To examine and compare treatment 
outcomes and economic beneﬁts in metastatic colorectal
cancer with an oral ﬂuoropyrimidine, capecitabine, versus
comparison therapies.
METHODS: A retrospective, matched-cohort study
design was used to abstract medical and retail pharmacy
claims records of 271 metastatic colorectal cancer
patients from a managed care, disease management 
database over a 30-month period. Patients were matched
in two study cohorts based on their treatment,
capecitabine (n = 78) vs. 5FULV +/- irinotecan (CPT) (n
= 193). The 5FU comparison cohort was comprised of
three therapy sub-groups: 5FULV (n = 78), 5FULV then
CPT (n = 78), and 5FULV plus CPT (n = 37). Time to
treatment discontinuation and survival were compared
between cohorts. The total direct cost of cancer care 
was captured through reimbursement claims. Cost-
effectiveness (cost per treatment duration) was calculated
for both cohorts.
RESULTS: Patients were well matched by age, gender,
metastases and co-morbidity status. Time to treatment
discontinuation with capecitabine was not signiﬁcantly
different than the comparison cohort (79 days vs. 104
days). Median estimated survival for capecitabine was
favorable relative to the comparison cohort (599 days 
vs. 530 days, p = 0.05). The total direct cost of cancer
care per patient was lower for capecitabine ($6,007 vs.
$13,339). Consequently cost-effectiveness ratio per
patient was lower for capecitabine than for the com-
